多西他赛联合表柔比星新辅助化疗治疗乳腺癌的疗效  

Effect of docetaxel combined with epirubicin neoadjuvant chemotherapy in breast cancer

作　　者：张波[1] 陈明贤[1] 陈怀云 ZHANG Bo;CHEN Ming-xian;CHEN Huai-yun(Oncology Department,the First People＇s Hospital of Zaoyang,Zaoyang 442100,China)

机构地区：[1]湖北省枣阳市第一人民医院肿瘤科,湖北枣阳441200

出　　处：《临床医学研究与实践》2018年第20期16-17,共2页Clinical Research and Practice

摘　　要：目的分析多西他赛联合表柔比星新辅助化疗治疗乳腺癌的应用与疗效。方法选择2015年7月至2017年7月我院收治的100例乳腺癌者为研究对象,依照就诊顺序将其分为两组,每组50例。观察组使用多西他赛+表柔比星治疗,对照组使用紫杉醇+表柔比星治疗。比较两组患者的治疗效果。结果观察组患者的韵砸砸显著高于对照组(P<0.05)。观察组患者的外周静脉炎、白细胞数量下降、胃肠道不良反应发生率低于对照组(P<0.05)。治疗后随访1年,观察组患者的复发率低于对照组,生存率高于对照组(P<0.05)。结论对于乳腺癌患者,多西他赛联合表柔比星新辅助化疗疗效显著,毒性反应发生率及复发率低,生存率高,值得临床推广使用。Objective To analyze the application and efficacy of doceta xel combined with epirubicin neoadjuvant chemotherapy in the treatment of breast cancer.Methods A total of 100 cases of breast cancer admitted in our hospital from July 2015 to July 2017 were selected and divided into two groups according to the order of treatment, with 50 cases in each group. The observation group was treated with docetaxel combined with epirubicin, while the control group was treated with paclitaxel combined with epirubicin. The clinical effects of the two groups were compared.Results The ORR in the observation group was significantly higher than that of the control group（P〈0.05）. The incidences of peripheral phlebitis,decrease of white blood cell count and gastrointestinal adverse reactions in the observation group were lower than those in the control group（P〈0.05）. After follow-up for 1 year after treatment, the recurrence rate of the observation group was lower than that of the control group, the survival rate was higher than that of the control group（P〈0.05）.Conclusion For the patients with breast cancer, docetaxel combined with epirubicin neoadjuvant chemotherapy has significant efficacy, low incidence of toxic reaction and recurrence rate, and high survival rate, which is worthy of clinical promotion and application.

关 键 词：多西他赛 表柔比星 新辅助化疗 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]